Mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof

1. Developmentally potent mesenchymal stem cells prepared according to a method comprising contacting mesenchymal stem cells with an effective amount of substituted deoxynucleotide or deoxynucleoside for an effective period, further comprising the step of co-culturing the mesenchymal stem cells contacted with substituted deoxynucleotide or deoxynucleoside with neural-lineage cells or media conditioned with neural-lineage cells, wherein the substituted deoxynucleotide or deoxynucleoside-contacted, mesenchymal stem cells become developmentally potent mesenchymal stem cells capable of differentiating to cells of neural lineage, with or without further comprising the step of contacting the mesenchymal stem cells with heparin, a growth factor or substituted deoxynucleotide or deoxynucleoside in an uncoated flask or a flask that has been treated to repel the cells, and wherein the substituted deoxynucleotide or deoxynucleoside is bromodeoxyuridine, bromodeoxycytidine, bromodeoxyguanosine, methyldeoxythymidine, or chlorodeoxyuridine.

2. Developmentally potent mesenchymal stem cells of claim 1 , wherein the cells form a cluster of two or more cells.

3. Developmentally potent mesenchymal stem cells of claim 2 , wherein the cluster of cells comprise less than about 50 percent redifferentiated cells.

4. Developmentally potent mesenchymal stem cells of claim 2 , wherein the cluster of cells comprise less than about 25 percent redifferentiated cells.

5. Developmentally potent mesenchymal stem cells of claim 2 , wherein the cluster of cells comprise less than about 10 percent redifferentiated cells.

6. Developmentally potent mesenchymal stem cells of claim 2 , wherein the cluster of cells comprise less than about 5 percent redifferentiated cells.

7. Developmentally potent mesenchymal stem cells of claim 2 , wherein the cluster of cells comprise less than about 1 percent redifferentiated cells.

8. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier or excipient and developmentally potent mesenchymal stem cells prepared according to the methods of claim 1 .

9. A cellular preparation comprising, as an active ingredient, developmentally potent mesenchymal stem cells of claim 1 , 2 , 3 , 4 , 5 , 6 or 7 .

10. A pharmaceutical composition comprising developmentally potent mesenchymal stem cells of claim 1 , 2 , 3 , 4 , 5 , 6 or 7 .

11. The pharmaceutical composition according to claim 10 further comprising a pharmaceutically acceptable carrier.

12. A cell having a second developmental potential phenotype prepared according to a method comprising the steps of:

a) contacting a cell of a first developmental potential phenotype with an effective amount of substituted deoxynucleotide or deoxynucleoside for an effective period that causes the cell to change into a second developmental potential phenotype distinct from the first developmental potential phenotype; and

b) co-culturing the substituted deoxynucleotide or deoxynucleoside-contacted cell of a) with neural-lineage cells or media conditioned with neural-lineage cells,

wherein the first developmental potential phenotype is a less developmentally potent mesenchymal stem cell;

wherein said second developmental potential phenotype is a more developmentally potent mesenchymal stem cell capable of differentiating into a cell of neural lineage; and

wherein the substituted deoxynucleotide or deoxynucleoside is bromodeoxyuridine, bromodeoxycytidine, bromodeoxyguanosine, methyldeoxythymidine or chlorodeoxyuridine.

13. The developmentally potent mesenchymal stem cells of any one of claim 1 , 2 , 3 , 4 , 5 , 6 or 7 wherein the substituted deoxynucleotide or deoxynucleoside is bromodeoxyuridine.

14. The cell having a second developmental potential phenotype of claim 12 wherein the substituted deoxynucleotide or deoxynucleoside is bromodeoxyuridine.

15. Developmentally potent mesenchymal stem cells prepared according to a method comprising contacting mesenchymal stem cells with an effective amount of substituted deoxynucleotide or deoxynucleoside for at least three days, wherein the substituted deoxynucleotide or deoxynucleoside-contacted, mesenchymal stem cells become developmentally potent mesenchymal stem cells capable of differentiating to cells of neural lineage, with or without further comprising the step of contacting the mesenchymal stem cell with heparin, a growth factor or substituted deoxynucleotide or deoxynucleoside in an uncoated flask or a flask that has been treated to repel the cells, and wherein the substituted deoxynucleotide or deoxynucleoside is bromodeoxyuridine, bromodeoxycytidine, bromodeoxyguanosine, methyldeoxythymidine, or chlorodeoxyuridine.

16. Developmentally potent mesenchymal stem cells of claim 15 , wherein the cells form a cluster of two or more cells.

17. Developmentally potent mesenchymal stem cells of claim 16 , wherein the cluster of cells comprise less than about 50 percent redifferentiated cells.

18. Developmentally potent mesenchymal stem cells of claim 16 , wherein the cluster of cells comprise less than about 25 percent redifferentiated cells.

19. Developmentally potent mesenchymal stem cells of claim 16 , wherein the cluster of cells comprise less than about 10 percent redifferentiated cells.

20. Developmentally potent mesenchymal stem cells of claim 16 , wherein the cluster of cells comprise less than about 5 percent redifferentiated cells.

21. Developmentally potent mesenchymal stem cells of claim 16 , wherein the cluster of cells comprise less than about 1 percent redifferentiated cells.

22. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier or excipient and developmentally potent mesenchymal stem cells of claim 15 .

23. A cellular preparation comprising, as an active ingredient, developmentally potent mesenchymal stem cells of any one of claim 15 , 16 , 17 , 18 , 19 , 20 , or 21 .

24. A pharmaceutical composition comprising developmentally potent mesenchymal stem cells of any one of claim 15 , 16 , 17 , 18 , 19 , 20 , or 21 .

25. The pharmaceutical composition according to claim 24 further comprising a pharmaceutically acceptable carrier.

26. A method for making developmentally potent mesenchymal stem cells capable of differentiating to cells of neural linage, the method comprising the steps of contacting mesenchymal stem cells with an effective amount of substituted deoxynucleotide or deoxynucleoside for an effective period; and co-culturing the mesenchymal stem cells contacted with substituted deoxynucleotide or deoxynucleoside with neural-lineage cells or media conditioned with neural-lineage cells, wherein the substituted deoxynucleotide or deoxynucleoside-contacted, mesenchymal stem cells become developmentally potent mesenchymal stem cells capable of differentiating to cells of neural lineage, with or without further comprising the step of contacting the mesenchymal stem cells with heparin, a growth factor or substituted deoxynucleotide or deoxynucleoside in an uncoated flask or a flask that has been treated to repel the cells, and wherein the substituted deoxynucleotide or deoxynucleoside is bromodeoxyuridine, bromodeoxycytidine, bromodeoxyguanosine, methyldeoxythymidine, or chlorodeoxyuridine.

27. The method of claim 26 wherein the developmentally potent mesenchymal stem cells form a cluster of two or more cells.

28. The method of claim 26 further comprising contacting the mesenchymal stem cells with a growth factor.

29. The method of claim 28 wherein the growth factor is fibroblast growth factor, epidermal growth factor or a combination thereof.

30. The method of claim 28 wherein the growth factor is fibroblast growth factor or epidermal growth factor.

31. The method of claim 28 wherein the growth factor is fibroblast growth factor.

32. The method of claim 28 wherein the growth factor is epidermal growth factor.

33. The method of claim 26 further comprising the step of contacting the mesenchymal stem cells with heparin.

34. The method of claim 26 wherein the mesenchymal stem cells are obtained from a zygote, blastocyst, embryo, fetus, infant juvenile or adult.

35. The method of claim 26 wherein the mesenchymal stem cells are obtained from a human.

36. A method for changing a developmental potential phenotype of mesenshymal stem cells, comprising the steps of contacting mesenchymal stem cells of a first developmental potential phenotype with an effective amount of substituted deoxynucleotide or deoxynucleoside for an effective period that causes the mesenchymal stem cells to change into a second developmental potential phenotype distinct from the first developmental potential phenotype; and co-culturing the substituted deoxynucleotide or deoxynucleoside contacted mesenchymal stem cells with neural-lineage cells or media conditioned with neural-lineage cells, wherein said second developmental potential phenotype is capable of developing to cells of neural lineage, and wherein the substituted deoxynucleotide or deoxynucleoside is bromodeoxyuridine, bromodeoxycytidine, bromodeoxyguanosine, methyldeoxythymidine, or chlorodeoxyuridine.

37. A method for making developmentally potent mesenchymal stem cells capable of differentiating to cells of neural Image from mesenchymal stem cells, the method comprising contacting mesenchymal stem cells with an effective amount of substituted deoxynucleotide or deoxynucleoside for at least three days, wherein the substituted deoxynucleotide or deoxynucleoside-contacted mesenchymal stem cells become developmentally potent mesenchymal stem cells capable of differentiating to cells of neural lineage, with or without further comprising the step of contacting the mesenchymal stem cell with heparin, a growth factor or substituted deoxynucleotide or deoxynucleoside in an uncoated flask or a flask that has been treated to repel the cells, and wherein the substituted deoxynucleotide or deoxynucleoside is bromodeoxyuridine, bromodeoxycytidine, bromodeoxyguanosine, methyldeoxythymidine, or chlorodeoxyuridine.

38. The method of claim 37 wherein the mesenchymal stem cells are contacted with substituted deoxynucleotide or deoxynucleoside in an uncoated flask or a flask that has been treated to repel the cells.

39. The method of claim 37 wherein the developmentally potent mesenchymal stem cells form a cluster of two or more cells.

40. The method of claim 37 further comprising contacting the mesenchymal stem cells with a growth factor.

41. The method of claim 40 wherein the growth factor is fibroblast growth factor, epidermal growth factor or a combination thereof.

42. The method of claim 40 wherein the growth factor is fibroblast growth factor.

43. The method of claim 40 wherein the growth factor is epidermal growth factor.

44. The method of claim 37 further comprising the step of contacting the mesenchymal stem cells with heparin.

45. The method of claim 37 wherein the mesenchymal stem cells are obtained from a zygote, blastocyst, embryo, fetus, infant juvenile or adult.

46. The method of claim 37 wherein the mesenchymal stem cells are obtained from a human.